143 related articles for article (PubMed ID: 6436731)
21. Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.
Morimoto S; Matsumura Y; Ohyama T; Shinyama H; Ichihara T; Takahashi Y; Hisaki K
Jpn J Pharmacol; 1990 Mar; 52(3):431-9. PubMed ID: 2110272
[TBL] [Abstract][Full Text] [Related]
22. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Maruyama W; Naoi M; Narabayashi H
J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
[TBL] [Abstract][Full Text] [Related]
23. Effect of L-threo-3,4-dihydroxyphenylserine(L-threo-DOPS) on brain and serum MHPG levels in mice: evidence for NE formation in CNS.
Karai N; Kato T; Katsuyama M; Nakamura M; Katsube J
Life Sci; 1987 Jun; 40(23):2261-8. PubMed ID: 3108598
[TBL] [Abstract][Full Text] [Related]
24. [The effect of L-threo-DOPS on P-300 in parkinsonism].
Yokota J; Itoh T; Imai H; Narabayashi H
Rinsho Shinkeigaku; 1990 May; 30(5):499-504. PubMed ID: 2119267
[TBL] [Abstract][Full Text] [Related]
25. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
26. Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats.
Araki H; Tanaka C; Fujiwara H; Nakamura M; Ohmura I
J Pharm Pharmacol; 1981 Dec; 33(12):772-7. PubMed ID: 6121848
[TBL] [Abstract][Full Text] [Related]
27. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
Azuma T; Suzuki T; Sakoda S; Mizuno R; Tsujino S; Kobayashi T; Kishimoto S; Hiraga T; Matsubara T; Yoshida S
Acta Neurol Scand; 1991 Jul; 84(1):46-50. PubMed ID: 1656690
[TBL] [Abstract][Full Text] [Related]
28. [Inhibition of harmaline induced tremor by L-threo-3, 4-dihydroxyphenylserine, an L-norepinephrine precursor].
Yamazaki M; Ikeda Y; Ishikawa M; Inagaki C; Tanaka C
Nihon Yakurigaku Zasshi; 1976 Apr; 72(3):363-9. PubMed ID: 986992
[TBL] [Abstract][Full Text] [Related]
29. Effects of L-threo-3,4-dihydroxyphenylserine on efflux of monoamines and acetylcholine in guinea pig brain.
Nishino N; Fujii Y; Kondo M; Shuntoh H; Fujiwara H; Tanaka C
J Pharmacol Exp Ther; 1987 Aug; 242(2):621-8. PubMed ID: 3112367
[TBL] [Abstract][Full Text] [Related]
30. A new metabolic pathway of L-threo-3,4-dihydroxyphenylserine, a precursor amino acid of norepinephrine, in the brain. Studies by in vivo microdialysis.
Maruyama W; Nakahara D; Naoi M
J Neural Transm Park Dis Dement Sect; 1994; 7(1):21-33. PubMed ID: 8579767
[TBL] [Abstract][Full Text] [Related]
31. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine.
Bartholini J; Constantinidis J; Puig M; Tissot R; Pletscher A
J Pharmacol Exp Ther; 1975 May; 193(2):523-32. PubMed ID: 1142103
[TBL] [Abstract][Full Text] [Related]
32. [L-threo-DOPS therapy and parkinsonism].
Narabayashi H
No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
[No Abstract] [Full Text] [Related]
33. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Tohgi H; Abe T; Takahashi S
J Neural Transm Park Dis Dement Sect; 1993; 5(1):27-34. PubMed ID: 8439390
[TBL] [Abstract][Full Text] [Related]
34. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on catecholamine levels in plasma and cerebrospinal fluid (CSF) in anesthetized rats.
Ishikawa Y; Kato Y; Murakami Y; Inoue T; Koshiyama H; Imura H
Proc Soc Exp Biol Med; 1987 Feb; 184(2):197-200. PubMed ID: 3101067
[TBL] [Abstract][Full Text] [Related]
35. Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy.
Suzuki T; Higa S; Tsuge I; Sakoda S; Hayashi A; Yamamura Y; Takaba Y; Nakajima A
Eur J Clin Pharmacol; 1980 Jun; 17(6):429-35. PubMed ID: 6772451
[TBL] [Abstract][Full Text] [Related]
36. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Goldstein DS; Holmes C; Sewell L; Pechnik S; Kopin IJ
J Clin Pharmacol; 2011 Jan; 51(1):66-74. PubMed ID: 20220040
[TBL] [Abstract][Full Text] [Related]
37. Age-related changes in the chronotropic effect and the enzymic decarboxylation of L-threo-3,4-dihydroxphenylserine in the rat heart.
Araki H; Fujiwara H; Tanaka C
J Pharm Pharmacol; 1981 Dec; 33(12):778-82. PubMed ID: 6121849
[TBL] [Abstract][Full Text] [Related]
38. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa.
Kato T; Karai N; Katsuyama M; Nakamura M; Katsube J
Biochem Pharmacol; 1987 Sep; 36(18):3051-7. PubMed ID: 3115271
[TBL] [Abstract][Full Text] [Related]
39. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS), an immediate precursor of norepinephrine, on the cerebral blood flow in rats.
Sato E; Irie T; Katsube J
Jpn J Pharmacol; 1987 Jan; 43(1):91-3. PubMed ID: 3106684
[TBL] [Abstract][Full Text] [Related]
40. Preferential decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat renal tissues.
Soares-da-Silva P
Gen Pharmacol; 1993 Jan; 24(1):75-81. PubMed ID: 8482506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
